Highlights From the AMPLITUDE Study at ASCO 2025
Key Points
-
Experts discuss poly (ADP-ribose) polymerase (ADP) inhibition for metastatic castration-sensitive prostate cancer (mCSPC).
-
The AMPLITUDE study evaluated the PARP inhibitor niraparib and abiraterone acetate plus prednisone (AAP) versus placebo plus AAP in mCSPC.
-
Data could expand the use of PARP inhibitors beyond their current approval in the metastatic castration-resistant disease setting.
One of the standout studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was the phase 3 AMPLITUDE trial, according to Michael Serzan, MD, of Dana-Farber Cancer Institute.
The study evaluated niraparib, a PARP inhibitor, and AAP versus placebo plus AAP in patients with mCSPC. Results showed that the risk of radiographic progression or death was reduced by 37% with niraparib plus AAP compared with placebo plus AAP.
Although PARP inhibitors are already approved for the treatment of mCSPC, Dr. Serzan shared his excitement in seeing their effect earlier in the disease course during an interview with Albert Jang, MD, of University Hospitals of Cleveland.
Given that patients with mCSPC may remain on treatment for many years, Dr. Serzan highlighted the importance of balancing the potential benefits of novel therapies with their long-term toxicities.